Old Well Partners’s Pasithea Therapeutics KTTA Stock Holding History

Old Well Partners’s Portfolio KTTA Stock Details KTTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,650	Closed	-$42K	–	38
2022 Q3	$42K	Buy	+1,650	New	+$38.7K	0.03%	39

Other funds holding KTTA

KPF

K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Old Well Partners's KTTA Position: Q4 2022 in Review

Old Well Partners sold out of Pasithea Therapeutics (KTTA) in Q4 2022, closing a stake of 1,650 shares — an estimated $42K sold.

Old Well Partners first reported a position in KTTA in Q3 2022 and held it in 1 quarter. The position peaked at $42K in Q3 2022. 11 funds tracked by Wall St. Rank hold KTTA as of Q4 2022.

Old Well Partners reported no remaining Pasithea Therapeutics position as of Q4 2022 after selling out during the quarter.
Old Well Partners sold 1,650 Pasithea Therapeutics shares in Q4 2022, an estimated $42K.
Old Well Partners first reported a position in Pasithea Therapeutics in Q3 2022 and held it in 1 quarter.
Old Well Partners's Pasithea Therapeutics position peaked at $42K in Q3 2022.
11 funds tracked by Wall St. Rank held Pasithea Therapeutics as of Q4 2022.

Based on Old Well Partners's 13F filing for Q4 2022, filed 14 Feb 2023.